当前位置: X-MOL 学术Chem. Bio. Drug Des. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Sertraline/ICG-loaded liposome for dual-modality imaging and effective chemo-photothermal combination therapy against metastatic clear cell renal cell carcinoma.
Chemical Biology & Drug Design ( IF 3 ) Pub Date : 2019-12-09 , DOI: 10.1111/cbdd.13652
Yuting Lei 1 , Li Zeng 1, 2 , Shuqing Xie 1 , Kui Fan 1 , Yuan Yu 1 , Jianwei Chen 1 , Siliang Zhang 1 , Zhigang Wang 2 , Ling Zhong 1
Affiliation  

A large number of chemotherapeutic drugs, utilized in the treatment of advanced metastatic clear cell renal cell carcinoma, are typically prone to poor biocompatibility, lack of targeting specificity, and high toxicity, which mostly leads to unsatisfactory clinical outcomes. As a new drug delivery pathway, nanoliposomes have the advantages of simplifying metabolism, reducing drug side-effects, and providing specific targeting, which can potentially improve the therapeutic effect toward tumor therapy. In this study, a clinically integrated nanoliposome containing Sertraline Hydrochloride and indocyanine green (ICG), here named as Ser/ICG@Lip, was successfully synthesized by film-dispersion and hydration-sonication methods. The photoacoustic imaging and near-infrared fluorescence imaging capabilities of this novel nanoliposome were validated in vitro. The high encapsulation rate of Sertraline Hydrochloride and ICG ensured the safety and therapeutic efficacy of the particle. Moreover, our results suggest that chemo-photothermal combination therapy can be more effective than single photothermal or chemotherapy treatments against malignant tumor cells. This is the first study introducing Sertraline Hydrochloride as a liposome-encapsulated chemotherapeutic agent, containing photothermal capabilities, for the treatment of metastatic renal clear cell cancer cells. This novel drug system has potential to evolve into an alternate treatment method for metastatic clear cell renal cell carcinoma.

中文翻译:

舍曲林/ ICG脂质体用于转移性透明细胞肾细胞癌的双模式成像和有效的化学-光热联合治疗。

用于治疗晚期转移性透明细胞肾细胞癌的大量化学治疗药物通常倾向于生物相容性差,缺乏靶向特异性和高毒性,这大多会导致临床效果不理想。作为一种新的药物输送途径,纳米脂质体具有简化代谢,减少药物副作用以及提供特异性靶向的优势,这可以潜在地改善对肿瘤治疗的治疗效果。在这项研究中,通过膜分散和水化超声方法成功地合成了临床上集成的含有盐酸舍曲林和吲哚菁绿(ICG)的纳米脂质体,在这里被称为Ser / ICG @ Lip。在体外验证了这种新型纳米脂质体的光声成像和近红外荧光成像功能。盐酸舍曲林和ICG的高包封率确保了该颗粒的安全性和治疗功效。此外,我们的结果表明化学-光热联合疗法比单一光热或化学疗法对恶性肿瘤细胞更有效。这是首次引入盐酸舍曲林盐酸盐作为脂质体包裹的化学治疗剂的研究,该药剂具有光热功能,可用于治疗转移性肾透明细胞癌细胞。这种新的药物系统具有发展成为转移性透明细胞肾细胞癌的替代治疗方法的潜力。盐酸舍曲林和ICG的高包封率确保了该颗粒的安全性和治疗功效。此外,我们的结果表明化学-光热联合疗法比单一光热或化学疗法对恶性肿瘤细胞更有效。这是首次引入盐酸舍曲林盐酸盐作为脂质体包裹的化学治疗剂的研究,该药剂具有光热功能,可用于治疗转移性肾透明细胞癌细胞。这种新型药物系统具有发展成为转移性透明细胞肾细胞癌的替代治疗方法的潜力。盐酸舍曲林和ICG的高包封率确保了该颗粒的安全性和治疗功效。此外,我们的结果表明化学-光热联合疗法比单一光热或化学疗法对恶性肿瘤细胞更有效。这是首次引入盐酸舍曲林盐酸盐作为脂质体包裹的化学治疗剂的研究,该药剂具有光热功能,可用于治疗转移性肾透明细胞癌细胞。这种新型药物系统具有发展成为转移性透明细胞肾细胞癌的替代治疗方法的潜力。我们的结果表明,化学-光热联合疗法比单一光热或化学疗法对恶性肿瘤细胞更有效。这是首次引入盐酸舍曲林盐酸盐作为脂质体包裹的化学治疗剂的研究,该药剂具有光热功能,可用于治疗转移性肾透明细胞癌细胞。这种新的药物系统具有发展成为转移性透明细胞肾细胞癌的替代治疗方法的潜力。我们的结果表明,化学-光热联合疗法比单一光热或化学疗法对恶性肿瘤细胞更有效。这是首次引入盐酸舍曲林盐酸盐作为脂质体包裹的化学治疗剂的研究,该药剂具有光热功能,可用于治疗转移性肾透明细胞癌细胞。这种新型药物系统具有发展成为转移性透明细胞肾细胞癌的替代治疗方法的潜力。
更新日期:2020-01-14
down
wechat
bug